Fibro Daily

FDA Says “No” to CFS Drug

Fibro Daily February 5, 2013

The Food and Drug Administration (FDA) has said “no” to a new drug called rintatolimod (Ampligen) made by Hemispherx Inc. for the treatment of chronic fatigue syndrome (CFS). The FDA wants to see more data and a new clinical trial before it approves its use.

In December, the Members of the Arthritis Advisory Committee voted against the use of the drug 9-5 due to inadequate data provided by Hemispherx. The FDA usually follows such recommendations, though no legal obligation exists for it follow them.

Comments

comments

Powered by Facebook Comments

Tagged with:

Comments are closed.

Login to your account

Can't remember your Password ?

Register for this site!